Credited with performing the first ever endovascular repair procedure in 1990
TEL AVIV, Israel, July 14, 2022 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced the appointment of endovascular pioneer Dr. Juan Parodi as a strategic advisor to the Company.
Marvin Slosman, Chief Executive Officer of InspireMD, commented, “Dr. Parodi’s world renowned achievements in the field of vascular surgery are remarkable, including having performed the first ever endovascular repair procedure in 1990. He also performed the first carotid TCAR procedure in 1994, utilizing reverse flow for cerebral protection. Dr. Parodi offers our company incredible experience, unique perspective and guidance as we build new solutions to advance stroke prevention and long-term patient outcomes, across the broadest range of vascular specialists and device options.”
Dr. Parodi stated, “My passion and years of work advancing breakthrough technology and clinical solutions is what drew me to the InspireMD team, as they exemplify a company with innovation in its DNA, building solutions that are practical, meaningful, market driven and foundationally driven by clinical performance as measured by patient outcomes. I believe CGuard™ EPS, with its unique conformability and proprietary MicroNet mesh protection, offers carotid artery disease patients’ better outcomes and greater long-term protection from post-procedural cerebral embolization than competing stents currently on the market. The transition of carotid disease management from open surgery to endovascular standard of care is well underway and being aligned with InspireMD offers a unique opportunity to contribute to their good work leading this important change.”
Dr. Parodi currently serves as Honorary Professor of Surgery at both Universidad de Buenos Aires in Argentina and at Washington University School of Medicine in St. Louis. Dr. Parodi received his Physician and Surgeon Honor Certificate from Universidad del Salvador, Buenos Aires, Argentina, his Board Certificate in General Surgery from the University of Buenos Aires, and his Board Certificate in Vascular Surgery from the Argentinean College of Medicine Argentinean College of Cardiovascular Surgery, Buenos Aires Province.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.
We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
investor-relations@inspiremd.com
